Interim report January-March 2006

• Sales increased by 51 percent, to SEK 46.0 (30.5) million. Exclusive of the acquired Swemed, the increase was 20 percent. • Gross income amounted to SEK 30.1 (20.6) million, an increase of 46 percent, and the gross margin to 65 percent (67). • Operating income amounted to SEK 5.4 (5.4) million. Last year’s operating income included an item of a one-time nature of SEK 2.4 million. Adjusted for this item operating income increased by 82 percent. • Net income for the Group was SEK 4.3 (6.2) million. • Earnings per share amounted to SEK 0.22 (0.34). • The equity/assets ratio amounted to 77 percent (83). • In January 2006 Swemed was acquired, which manufactures and markets medical device products for in vitro fertilization. Swemed has been consolidated as from January 1, 2006. The integration work is running according to plan. • A new product within the transplantation area, Steen Solution™, was approved for sales, so-called CE marking, in Europe in January. • ClearVision™ Embryo Transfer Catheter, for reintroduction of the embryo into the uterus, was approved for sales, so-called 510(k) approval, in the USA in February. May 4, 2006 Kungsbacka, Sweden Magnus Nilsson CEO Questions should be addressed to: Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61. Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

---